Abstract
Vif is an HIV accessory protein whose primary function is to negate the action of APOBEC3G, a naturally occurring cellular inhibitor of HIV replication. Vif acts by binding to APOBEC3G, inducing its protein degradation within infected cells and reducing its levels in progeny virions. Interventions that interfere with the Vif-APOBEC3G interaction, raise intracellular or virion associated levels of APOBEC3G, or reduce intracellular levels of Vif, all could hold promise as potential therapeutic approaches aimed at enhancing the cells innate antiviral activity. Levels of APOBEC3G might be increased or Vif levels decreased, by strategies targeting protein synthesis, protein degradation or cellular localisation and function, and properties of APOBEC3G and Vif relevant to these strategies are discussed. Recent data have suggested that Vif may have other mechanisms of action apart from the above activities against APOBEC3G, including effects against other anti-viral mechanisms independent of APOBEC3G cytidine deaminase activity. In addition to interaction with APOBEC3G, Vif may have other accessory functions, which are discussed in relation to potential therapies that may affect multiple stages of the HIV life cycle. Future development of strategies that combine enhancement of APBOEC3G functional with inhibition of multiple Vif functions may become useful tools for HIV therapy.
Keywords: Vif, APOBEC3G, HIV, viral accessory protein, anti-viral therapy, cellular inhibitor, ZIN, reverse transcription
Current Drug Targets
Title: Cellular Interactions of Virion Infectivity Factor (Vif) as Potential Therapeutic Targets: APOBEC3G and More?
Volume: 7 Issue: 12
Author(s): J. M. Carr, A. J. Davis, F. Feng, C. J. Burrell and P. Li
Affiliation:
Keywords: Vif, APOBEC3G, HIV, viral accessory protein, anti-viral therapy, cellular inhibitor, ZIN, reverse transcription
Abstract: Vif is an HIV accessory protein whose primary function is to negate the action of APOBEC3G, a naturally occurring cellular inhibitor of HIV replication. Vif acts by binding to APOBEC3G, inducing its protein degradation within infected cells and reducing its levels in progeny virions. Interventions that interfere with the Vif-APOBEC3G interaction, raise intracellular or virion associated levels of APOBEC3G, or reduce intracellular levels of Vif, all could hold promise as potential therapeutic approaches aimed at enhancing the cells innate antiviral activity. Levels of APOBEC3G might be increased or Vif levels decreased, by strategies targeting protein synthesis, protein degradation or cellular localisation and function, and properties of APOBEC3G and Vif relevant to these strategies are discussed. Recent data have suggested that Vif may have other mechanisms of action apart from the above activities against APOBEC3G, including effects against other anti-viral mechanisms independent of APOBEC3G cytidine deaminase activity. In addition to interaction with APOBEC3G, Vif may have other accessory functions, which are discussed in relation to potential therapies that may affect multiple stages of the HIV life cycle. Future development of strategies that combine enhancement of APBOEC3G functional with inhibition of multiple Vif functions may become useful tools for HIV therapy.
Export Options
About this article
Cite this article as:
Carr M. J., Davis J. A., Feng F., Burrell J. C. and Li P., Cellular Interactions of Virion Infectivity Factor (Vif) as Potential Therapeutic Targets: APOBEC3G and More?, Current Drug Targets 2006; 7 (12) . https://dx.doi.org/10.2174/138945006779025356
DOI https://dx.doi.org/10.2174/138945006779025356 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis
Current Pharmaceutical Analysis Synthesis and Biological Evaluations of 3-Benzothiazol-2-yl Coumarin Derivatives as MEK1 Inhibitors
Letters in Drug Design & Discovery Lycopene Protects Liver Against Ulcerative Colitis
Current Drug Therapy Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry Synthesis of Novel Amides Based on Acridone Scaffold with Interesting Antineoplastic Activity
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis Imaging Using 68Ga-RGD PET: Preliminary Report from Seoul National University Hospital
Current Medical Imaging Formulation of Nanoparticles Against TB - A Review
Recent Patents on Inflammation & Allergy Drug Discovery Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Editorial (Thematic Issue: Endothelium: A Target for Therapeutic Intervention)
Current Vascular Pharmacology Annona sp: Plants with Multiple Applications as Alternative Medicine - A Review
Current Bioactive Compounds Disorder in Milk Proteins: Formation, Structure, Function, Isolation and Applications of Casein Phosphopeptides
Current Protein & Peptide Science Advances in the Integration of Drug Metabolism into the Lead Optimization Paradigm
Mini-Reviews in Medicinal Chemistry Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery
Current Pharmaceutical Design Glycyrrhetinic Acid and Its Derivatives: Anti-Cancer and Cancer Chemopreventive Properties, Mechanisms of Action and Structure- Cytotoxic Activity Relationship
Current Medicinal Chemistry Nanoparticles in the Development of Therapeutic Cancer Vaccines
Pharmaceutical Nanotechnology Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma
Current Drug Delivery